Weekly Policy Update: Advocacy Around Drug Transparency Issues, an Opportunity To Be Heard By the Next Governor, and the Omnibus Spending Bill

Friday, March 23, 2018

This week CBSA testified in opposition to House Bill 1009, Diabetes Drug Pricing Transparency Act 2018. The bill was heard in the House Health, Insurance and Environment Committee and passed on a party line vote. It will now move to House Appropriations.  

Weekly Policy Update: Continuing the Transparency Advocacy and a Business Guide for the Governor

Friday, March 16, 2018


Weekly Policy Update: House Bill 1260 Prescription Drug Transparency, plus the Advamed Fly-In in Washington, D.C.

Friday, March 02, 2018

Urge a NO Vote on HB 1260, Prescription Drug Price Transparency 
Continue Reading

Weekly Policy Update: Positions on three bills, true transparency, and a visit to D.C.

Friday, February 23, 2018

Continue Reading

Weekly Policy Update: True Transparency and Medicare Stakeholder Input

Friday, February 16, 2018

Continue Reading

Weekly Policy Update: Colorado BioScience Association Highlights State's Life-Saving Medical Breakthroughs for Lawmakers

Friday, February 09, 2018

This week we had a successful CBSA Day at the Capitol. At the event we heard from Lieutenant Governor Donna Lynne on her top priorities, outlook on the opioid and substance abuse task force and the future of our state as it relates to healthcare. Lt. Governor’s remarks were a great opportunity for our companies to hear from State leadership and ask top of mind questions. Throughout the day CBSA members heard a report on the Association’s policy priorities, heard from legislators about their priorities, learned how to best engage legislators throughout the session, and garnered insight on the value of advocacy. We wrapped up the day with a life science showcase, which was a great opportunity for the Colorado General Assembly talk to our members and learn about the exciting innovations in our industry.  

Friday Policy Updates 2/2/2018

Friday, February 02, 2018

As things continue to be active and heat up over at the Colorado State Capitol, this week the Colorado BioScience Association took formal positions on three bills, while continuing to evaluate and make recommendations on legislation being introduced. Outlined below are further details - and encouragement to reach out to CBSA for your perspective.   

Friday Policy Updates 1/26/2018

Friday, January 26, 2018

Continue Reading

Friday Policy Update 1/19/2018

Friday, January 19, 2018

Another week goes by and we continue to strongly advocate for the repeal of the medical device excise tax. This week in DC, the House passed the continuing resolution (CR) to fund the government until February 16th. Included in the CR is a 2-year retroactive suspension of the device tax and a 6-year reauthorization of Children’s Health Insurance Program (CHIP), the longest reauthorization in CHIP’s history. Both would have a significant positive impact to our industry. The bill is now in the Senate’s hands, which we anticipate a vote today before midnight. At this time, it is unclear if the Senate has enough votes to pass the CR. If the House version of the CR does not pass, Congress will look to pass a clean, multi-day CR and have further discussions on a larger package that would address immigration, budget caps, and other issues. If the multi-day CR is the route Congress takes, it is likely the medical device excise tax will not be included   

Friday Policy Updates 1/12/2018

Friday, January 12, 2018

Continue Reading